OmniAb, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
OmniAb reported Q2 2026 revenue of $13.4M (vs. $3.9M YoY), driven by milestone and service revenue. The company raised full-year 2026 revenue guidance to $32–36M (from $28–33M) and cash end-of-year guidance to $37–41M (from $33–38M). As of June 30, 2026, OmniAb held $52.0M in cash/equivalents/short-term investments, with 110 active partners and 425 active programs including 34 in clinical development or commercialization.
Why this rating
Revenue growth 3.4× YoY and raised guidance materially positive; however, company still unprofitable ($13.6M H1 loss) and guidance raise is modest relative to ~$145M market cap—real but not transformational.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.